Invention Grant
- Patent Title: Antibodies targeting PDL1 and methods of use thereof
-
Application No.: US16753876Application Date: 2018-10-09
-
Publication No.: US12077588B2Publication Date: 2024-09-03
- Inventor: Tea Gunde , Matthias Brock , Christian Hess , Alexandre Simonin
- Applicant: Numab Therapeutics AG
- Applicant Address: CH Wädenswil
- Assignee: Numab Therapeutics AG
- Current Assignee: Numab Therapeutics AG
- Current Assignee Address: CH Horgen
- Agency: Prismatic Law Group, PLLC
- Agent Ronald J. Kamis
- Priority: EP 195781 2017.10.10 EP 167094 2018.04.12 EP 180816 2018.06.29
- International Application: PCT/EP2018/077511 2018.10.09
- International Announcement: WO2019/072869A 2019.04.18
- Date entered country: 2020-04-06
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A61P35/00 ; C07K16/28 ; A61K39/00
Abstract:
The present invention relates to an isolated antibody which specifically binds human PDL 1, and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid encoding said antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibody.
Public/Granted literature
- US20200283528A1 ANTIBODIES TARGETING PDL1 AND METHODS OF USE THEREOF Public/Granted day:2020-09-10
Information query
